- Home
- TBLD vs AQST Comparison
TBLD vs AQST Comparison
Compare TBLD & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TBLD | AQST |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 647.4M | 707.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | TBLD | AQST |
|---|---|---|
| Price | $21.06 | $3.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.83 |
| AVG Volume (30 Days) | 69.5K | ★ 6.3M |
| Earning Date | 01-01-0001 | 03-04-2026 |
| Dividend Yield | ★ 5.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,397,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $43.02 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.94 | $2.12 |
| 52 Week High | $21.12 | $7.55 |
Technical Indicators
Market Signals| Indicator | TBLD | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 82.32 | 26.63 |
| Support Level | $20.41 | $3.17 |
| Resistance Level | $20.67 | $3.55 |
| Average True Range (ATR) | 0.23 | 0.27 |
| MACD | 0.06 | -0.06 |
| Stochastic Oscillator | 82.99 | 2.54 |
Price Performance
Historical ComparisonAbout TBLD Thornburg Income Builder Opportunities Trust
Thornburg Income Builder Opportunities Trust is a diversified, closed-end management investment company. The Trust's investment objective is to provide current income. The Trust will seek to achieve its investment objective by investing, directly or indirectly, at least 80% of its Managed Assets.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.